Maze Therapeutics (NASDAQ:MAZE) CEO Jason Coloma Sells 1,938 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 1,938 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $26.00, for a total value of $50,388.00. Following the sale, the chief executive officer directly owned 31,001 shares of the company’s stock, valued at approximately $806,026. This represents a 5.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Stock Down 4.1%

MAZE opened at $24.50 on Tuesday. The business has a 50 day moving average price of $33.00 and a two-hundred day moving average price of $37.92. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. The company has a market cap of $1.36 billion, a PE ratio of -9.68 and a beta of 2.50. Maze Therapeutics, Inc. has a 52 week low of $9.15 and a 52 week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The business had revenue of $20.00 million during the quarter. As a group, research analysts anticipate that Maze Therapeutics, Inc. will post -2.63 EPS for the current year.

Analyst Ratings Changes

Several analysts have commented on the company. Truist Financial reduced their price objective on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, April 14th. JPMorgan Chase & Co. upped their price objective on Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, March 31st. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Finally, Guggenheim increased their target price on Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $66.00.

Hedge Funds Weigh In On Maze Therapeutics

A number of large investors have recently modified their holdings of MAZE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Maze Therapeutics during the 1st quarter worth approximately $57,000. Goldman Sachs Group Inc. purchased a new position in shares of Maze Therapeutics during the 1st quarter worth approximately $145,000. Rhumbline Advisers purchased a new position in shares of Maze Therapeutics during the 1st quarter worth approximately $80,000. Geode Capital Management LLC raised its stake in shares of Maze Therapeutics by 8.8% during the 2nd quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock worth $2,838,000 after buying an additional 18,773 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in shares of Maze Therapeutics by 387.0% during the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after buying an additional 3,371 shares in the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.